tm logo
VEINOXA
ABANDONED - SECTION 38(11)

on 31 Dec 1969

Last Applicant/ Owned by

CANADIAN NEUTRICEUTICAL HEALTH INC.

13-365 Healey RdBolton

ONTARIO

CA

L7E5C1

Serial Number

2162736 filed on 27th Jan 2022

Correspondent Address

dba Trademark AngelSuite 521,6-2557 Dougall Avenue,Windsor,

ONTARIO

CA

N8X1T5

VEINOXA

Trademark usage description

anti-diabetic pharmaceuticals; anti-epileptic pharmaceutical preparations; antidiabetic pharmaceuticals; hemorrhoid preparations; herbal supplements f Read More

Classification Information


Class [005]
Anti-diabetic pharmaceuticals; anti-epileptic pharmaceutical preparations; antidiabetic pharmaceuticals; hemorrhoid preparations; herbal supplements for the treatment of the respiratory system; herbal supplements for use in dermatology, namely, dermatitis, eczema, psoriasis; injectable pharmaceutical contraceptives; mineral supplements; pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; pharmaceutical preparations for reducing cholesterol; pharmaceutical preparations for regulating the immune system; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for the relief of pain; pharmaceutical preparations for the treatment of acne; pharmaceutical preparations for the treatment of allergies; pharmaceutical preparations for the treatment of asthma; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; pharmaceutical preparations for the treatment of blood disorders; pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cardiovascular diseases; pharmaceutical preparations for the treatment of carpal tunnel syndrome; pharmaceutical preparations for the treatment of chronic pain; pharmaceutical preparations for the treatment of cranial or facial nerve disorders; pharmaceutical preparations for the treatment of degenerative nerve diseases and disorders, namely, Alzheimer's disease, Parkinson's disease, Huntington's disease and multiple sclerosis; pharmaceutical preparations for the treatment of dental and oral diseases; pharmaceutical preparations for the treatment of diabetes; pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; pharmaceutical preparations for the treatment of diseases, disorders and infections of the spinal cord systems and related cartilage and tissue; pharmaceutical preparations for the treatment of drug and alcohol abuse; pharmaceutical preparations for the treatment of gastro-intestinal diseases; pharmaceutical preparations for the treatment of genito-urinary and pelvic diseases, disorders and infections, namely infertility, sexually transmitted diseases, incontinence and sexual dysfunction; pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of glaucoma; pharmaceutical preparations for the treatment of gout; pharmaceutical preparations for the treatment of headaches; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes; pharmaceutical preparations for the treatment of infectious diseases, namely respiratory infections, eye infections; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases; pharmaceutical preparations for the treatment of inflammatory muscle diseases and disorders; pharmaceutical preparations for the treatment of motion sickness; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the treatment of myalgia and neuralgia; pharmaceutical preparations for the treatment of neurological diseases, namely, Alzheimer's, Huntington's Disease, cerebral palsy; pharmaceutical preparations for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of ophthalmological diseases and disorders; pharmaceutical preparations for the treatment of physical and psychological addictions, namely, gambling addiction, eating disorders and addictions, nicotine addiction, Internet addiction, drug addiction; pharmaceutical preparations for the treatment of psychiatric diseases, namely, mood disorders, anxiety disorders, cognitive disorders, schizophrenia; pharmaceutical preparations for the treatment of varicose veins; pharmaceutical preparations for the treatment of vascular diseases; pharmaceutical preparations for use in gastroenterology; pharmaceutical preparations for use in ocular disorders; pharmaceutical preparations for use in oncology; pharmaceutical preparations for use in ophthalmology; pharmaceutical products for ophthalmological use; preparations for treating hemorrhoids; tapes for varicose veins; vitamin and mineral dietary supplements; vitamin and mineral food supplements; vitamin and mineral preparations; vitamin and mineral supplements; vitamin supplements


Classification kind code

11

Mark Details


Serial Number

2162736

Mark Type

Trademark

Legal History


Action TakenStatus
Submitted for opposition 264
on 30th May 2024
Abandoned - Section 38(11) Opposition
Submitted for opposition 70
on 11th Jan 2024
Opposed
Submitted for opposition 110
on 31st Oct 2023
Proposed Opposition
Submitted for opposition 42
on 06th Sep 2023
Advertised
Submitted for opposition 27
on 14th Aug 2023
Approval Notice Sent
Submitted for opposition 26
on 14th Aug 2023
Approved
Submitted for opposition 22
on 08th Aug 2023
Search Recorded
Submitted for opposition 30
on 27th Jan 2022
Filed
Submitted for opposition 1
on 27th Jan 2022
Created
Submitted for opposition 31
on 27th Jan 2022
Formalized